Why Arcus Biosciences, Inc.’s (RCUS) Stock Is Up 9.51%
As of Tuesday, October 20, Arcus Biosciences, Inc.’s RCUS share price has surged by 9.51%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Commentary & Analysis
Why Arcus Biosciences, Inc.’s (RCUS) Stock Is Down 5.01%
As of Tuesday, October 13, Arcus Biosciences, Inc.’s RCUS share price has dipped by 5.01%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Arcus Biosciences, Inc.’s (RCUS) Stock Is Down 5.18%
As of Thursday, October 08, Arcus Biosciences, Inc.’s RCUS share price has dipped by 5.18%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Arcus Biosciences, Inc.’s (RCUS) Stock Is Down 5.42%
As of Thursday, September 24, Arcus Biosciences, Inc.’s RCUS share price has dipped by 5.42%, which has investors questioning if this is right time to buy.Michael Rose
Why Arcus Biosciences, Inc.’s (RCUS) Stock Is Down 5.43%
As of Friday, September 11, Arcus Biosciences, Inc.’s RCUS share price has dipped by 5.43%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | RCUS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,024.2 | $228.4 | 60% |
|
| Shares Out (Mil) | 126.1 | 53.9 | 67% |
|
| Institutional Ownership | 95.3% | 92.9% | 67% |
|
| Float (Mil) | 90.5 | 41.7 | 59% |
|
| Beta | 0.81 | 0.95 | 48% |
|
| Avg Daily Volume (000s) | 2,059 | 582 | 82% |
|
| Price Change (52-week) |
44.2% | 47.6% | 82% |
|
| Growth | RCUS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 25.9% | 13.6% | 87% |
|
| Net Income (5yr) | (23.5%) | (10.1%) | 18% |
|
| EPS (5yr) | (7.9%) | 15.8% | 23 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (20.6%) | (15.7%) | 32% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 9 | |
| Current EPS | ($0.893) | ($3.516) | ($3.123) | |
| Month Ago EPS | ($0.886) | ($3.530) | ($3.385) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($0.826) | ($3.483) | ($3.103) | |
| Year/Year Chg | 23.7% | 7.0% | (11.8%) | |
| Financials | RCUS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $117 | $37 | 28% |
|
| Net Income (TTM) (Mil) | ($460) | ($44) | 3% |
|
| EPS (TTM) | ($3.862) | ($1.500) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($474) | ($33) | 2% |
|
| Net Cash Flow (TTM) (Mil) | ($98) | $2 | 15% |
|
| Long-Term Debt (Q1) (Mil) | $225 | $4 | 51% |
|
| Enterprise Value (Q1) (Mil) | $3,026 | $177 | 55% |
|
| Valuation | RCUS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.51 | 2.19 | 85% |
|
| P/E | na | 19.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | RCUS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (324.8%) | 66.9% | 1% |
|
| Net Margin | (393.2%) | (73.7%) | 2% |
|
| ROA | (46.0%) | (47.1%) | 12% |
|
| ROE | (90.8%) | (54.1%) | 10% |
|
| Liabilities to Assets | 49.8% | 29.1% | 42% |
|
| F-Score | 0 | 2 | na |
|
Arcus Biosciences, Inc. did not pass any screens on 10/20/2026.
